|
**Overview**: Lupus Anticoagulant LAC Panel**Introduction**: The Lupus Anticoagulant LAC Panel is a diagnostic tool designed for comprehensive lupus anticoagulant screening using plasma samples. In India, APS is underdiagnosed in women with recurrent pregnancy loss (~1-5 percent) and young patients with unprovoked thrombosis, where LA positivity confers high thrombotic/obstetric risk. High morbidity from incomplete testing in rural/low-SES patients, limited coagulation labs, delayed warfarin/LMWH leading to recurrent events or fetal wastage. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for DRVVT screen/confirm, APTT, PT, LA ratio, anti-cardiolipin Ab, and anti-beta2 glycoprotein over 1-2 days with high accuracy, valuable for full APS laboratory criteria fulfillment. This diagnostic falls under coagulation screening and targets patients with thrombosis, miscarriage, or SLE, addressing accurate detection to guide lifelong anticoagulation, low-dose aspirin, or hydroxychloroquine. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise LA/APS profiling and reducing thrombotic/obstetric burden. Its plasma-based approach ensures reliable multi-assay evaluation.**Other Names**: LAC Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: Comprehensive LA panel standard; in India, used in thrombosis/rheumatology clinics.**Purpose**: The test assesses 7 parameters including DRVVT screen to guide comprehensive lupus anticoagulant screening, confirm APS, inform anticoagulation.**Test Parameters**: 1. DRVVT Screen, 2. DRVVT Confirm, 3. APTT, 4. PT, 5. Lupus Anticoagulant Ratio, 6. Anti-Cardiolipin Ab, 7. Anti-Beta2 Glycoprotein.**Pretest Condition**: No fasting required; patients should have thrombosis or obstetric history.**Specimen**: 3 mL plasma in NaCit tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve coagulation factors, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on thrombosis, miscarriage, SLE.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected APS including recurrent events, benefits of comprehensive screening, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive LA + anti-cardiolipin/beta2GP confirms APS, necessitating specialist input.**Specialist Consultation**: Hematologists/rheumatologists should be consulted for management.**Additional Supporting Tests**: Repeat testing in 12 weeks for confirmation.**Test Limitations**: Affected by anticoagulants; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Thrombosis Studies India 2023. |
